Table 3. Plasma and tumor Se levels achieved with oral aministration of 0.2gm/day MSC or SLM; correlation with “cure”, and tumor SN38 concentrations in A253, and FaDU xengrafts treated with irinotecan, 100 mg/kg/wkx4.

Se (0.2 mg)	Plasma Cmax (μM)	Tumor Se (nmol/gm)		“Cures” (%)		SN38 (nmol/gm)
		A253	FaDU	A253	FaDU	A253	FaDU
MSC	15	16	22	60	100	13.1	29.4
SLM	48	80	100	60	100	ND	ND